Rationale: Epilepsy surgery procedures started in Argentina more than 50 years ago. This is the first comprehensive and systematic survey of epilepsy surgery long-term outcome from our country. Methods: A descriptive cohort study was conducted between 1998 and 2008 for drug-resistant epilepsy surgery with a minimum of 12 months follow-up (n = 110). In 84 cases (76.36%) resective surgery was performed, and outcome periodically assessed using the Engel score. Patients were stratified into groups: 12, 13-36, 37-60 and over than 60 months of follow-up. Video-EEG with and without intracranial electrode implants, intraoperative electrocorticograms, Wada tests, pathology reports, use of antiepileptic drugs (AEDs), and surgical complication rates were evaluated. Results: Surgical techniques included: 69 lobectomies (62.7%), 15 lesionectomies (13.6%), 6 callosotomies (5.4%), 6 multiple subpial transection (5.4%), 11 vagus nerve stimulations (10%), 3 hemispherectomies (2.7%). Male: female ratio: 1/1.44. Mean age at time of surgery: 26.2 years. Mean duration of epilepsy: 14 years. Age at seizure onset: 11.5 years. Mean follow-up: 46 months. Pathology findings: mesial temporal sclerosis 32 (35.1%); dual pathology 17 (18.7%); cortical dysplasia 15 (16.4%); non-specific inflammatory changes 11 (12.1%); tumors 7 (7.7%); other 6 (6.8%). Engel scores at 12 months follow-up: 72.6% (61) class I, 16.6% (14) class II and 15.5% (13) class III-IV; 13-36 months after surgery: 68.1% of cases were class I, 15.9% class II and 15.5% class III-IV. After 37-60 months, 74% class I, 14% class II, 14% class III-IV. Over 60 months (n = 45) 78% class I, 13.5% class II and 8.1% class III-IV. Conclusion: Conducting a successful epilepsy surgery program in a developing country is challenging. These results should encourage specialists in these countries. Long-term outcome results comparable to centres in developed countries can be achieved.
ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Methods
A descriptive retrospective cohort study using information from refractory epilepsy and epilepsy surgery databases in our program was conducted, by analysing all patients operated between 1998 and 2008 for drug-resistant epilepsy. One hundred and fifty cases were operated on, only cases with a minimum of 12 months follow-up were included in the study (n = 110). In 84 cases (76.36%) resective surgery (was performed, and outcome periodically assessed using the Engel score (Table 1 ). Engel's score was systematically assessed by neurologists/epileptologists or neurosurgeons in follow up visits. When patients were not available for personal interview personally, Engel scores were obtained via telephone interview.
Patients were stratified into groups (Table 2) according to follow-up duration as follows: 12 months, 13-36 months, 37-60 months and over than 60 months.
Patients were grouped according procedure, namely: lobectomy, lesionectomy and corticectomy with and without multiple subpial transections.
A standard epilepsy MRI protocol was used to study all patients (GE 1.5 T GE Sigma Excite 1.5 T): sagital T1 sequences (5 mm slice thickness), coronal FLAIR (5 mm), T2 (3 mm), axial T1, T2 and T2* (5 mm), sequences of 3D T1 sequences and diffusion of 1.6 mm slice thickness.
Use of Video-EEG monitoring prior to surgery with and without intracranial electrode implants was also evaluated, as well as intraoperative electrocorticograms (ECoG) and Wada tests.
Pathology reports, number and dose of antiepileptic drugs (AEDs) before and after surgery, immediate and long term mortality and surgical complication rates were also analyzed.
Most of the patients received both pre and post-surgical neuropsychiatric and neurocognitive evaluations but the results were not analysed in this survey.
Results
Surgical techniques performed included: 69 lobectomies (62.7%), 15 lesionectomies (13.6%), 6 callosotomies (5.4%), 6 multiple subpial transection (5.4%), 11 vagus nerve stimulations (10%) and 3 hemispherectomies (2.7%).
AEDs were discontinued in 19 patients (17.3%), number of different AEDs decreased in 22 cases (20%), and drug dose was reduced in twelve patients (10.9%).
Mean follow-up in this group of patients was 46 months (range 12-126), with a male: female ratio of 1:1.44 (59.1% were females). Mean age at time of surgery was 26.2 AE 8 years (range 2-59), and mean duration of epilepsy 14 years. Age at seizure onset was 11.5 AE 6 years. (Table 1) .
In 91 patients (83%), pathology reports were obtained and findings included: mesial temporal sclerosis 32 (35.1%); dual pathology 17 (18.7%); cortical dysplasia 15 (16.4%) (Taylor type 40%); nonspecific inflammatory changes 11 (12.1%); tumors 7 (7.7%): ganglioglioma (3), oligodendroglioma (2), pilocytic astrocytoma (1), and low grade oligodendroastrocytoma (1); others 6 (6.8%): cavernomas (3), normal (3). Pathology examination was not performed in 19 cases (17%) (Two hemispherectomies, six callosotomies and eleven vagal nerve stimulations) (Fig. 1) .
All patients were evaluated by Video-EEG monitoring. Intracranial electrodes were implanted in 32 cases (29.1%), intraoperative ECoG was registered in 34 patients (30.9%) and Wada test conducted in 42 (38.2%). [ ( ) T D $ F I G ] In resective procedures, Engel scores at 12 months follow-up indicated 71.4% (60) of patients were class I, 15.5% (13) class II and 13.1% (11) class III and IV; 13-36 months after surgery (n = 67), we found 70.1% of cases were class I, 16.4% class II and 13.5% class III-IV.
Between 37 and 60 months of postoperative follow-up (50 patients), 72% of patients were class I, 14% were class II, while 14% were class III and IV; and over 60 months (n = 45) 71.1% of patients were class I, 13.3% class II and 15.5% class III-IV. (Fig. 2) .
Depending on the aetiology we found: mesial temporal sclerosis (MTS) was the most common diagnosis, observed in 38% (n = 32) of the total series. Twenty five of patients (78.1%) were class I at 1 year follow-up; 70% remained class 1 between 12 and 35 months; 69% between 36 and 60 months, and finally, in patients followed over 60 months (17 patients) we observed 77% continued in this class (Fig. 3) .
Cortical dysplasia accounted for 17.8% (n = 15), six of which were ''Taylor type''. In this subgroup, 11 patients (73.3%) were class I after 12 months follow-up, 2 patients (13.3%) class II and one patient class IV (6.6%). At 12-36 months follow-up 9 patients (82%) class I and 2 patients (18%) class II. Four patients were lost to follow up after 1 year.
Dual pathology accounted for 20.2% (n = 17). Eleven patients (64.7%) were class I after a year of follow-up, 3 patients (17.6%) were class II and 3 patients (17.6%) class III. At 12 to 36 months follow-up, 9 patients (64.3%) were class I, 3 (21.4%) and 2 (14.2%) class III. At 60 months 6 patients were class I, 2 (22.2%) class II and one (11.1%) class III. More than 60 months, 3 patients (60%) class I and 2 (40%) class II (Fig. 2) .
With respect to immediate and long term complications of the procedure: none were observed in 97 cases (88.2%); two patients suffered cranial nerve paresis with full recovery; subdural collections or hematomas responding to medical treatment were present in 2 cases, and transient motor paresis in 7 patients. Infection occurred in one patient and cerebral oedema also in one patient.
Two patients died during follow up, one committing suicide 10 years after surgery, and one from colon cancer 31 months after surgery.
Discussion
Based on follow up findings and a review of the literature, patients were classified as presenting (a) excellent results: when free of seizures (Engel class I); (b) good results: if without seizures, or suffering acute isolated seizures only (Engel class I and II); and (c) only mild changes: when no improvement or only moderate change was observed (class III and IV). Good outcome was observed in 89% of patients undergoing resective surgery regardless of aetiology or type of procedure, 72% of these showing excellent results at 1 year of follow-up.
Long-term outcome
Few published reports have addressed the outcome of epilepsy surgery after 5 years and even fewer have been conducted in developing or newly industrialized countries. Argentina is centralized around its capital city Buenos Aires, people from all over the country come to our centre seeking a comprehensive epilepsy program, making long-term outcome information collection difficult. Some few years ago, Cohen-Gadol et al. 12 pointed out that the reason patients lose or maintain contact with referral centres may be closely related to outcome status a bias which increased if patients had to travel long distances for their visits. Another important issue is that, as we used Engel's score only for resective surgeries and not for palliative ones, this may explain the high rates of excellent outcome results observed in this review. The group of patients followed for more than 60 months (n = 45) showed excellent outcome in 76.3% of cases.
A recently published meta-analysis 13 comparing long-term seizure control after temporal lobe surgery to medical treatment in patients with refractory temporal lobe epilepsy, found 44% of patients were seizure-free, vs. only 12% of those not operated. Although seizure control effectiveness has shown a trend to decrease as time after surgery increases (''running-down'' phenomenon), [14] [15] [16] no evidence of this was observed in our series.
Types of procedure
Resective procedures achieved best results (70% excellent performance), while palliative procedures showed much lower success rates.
Temporal lobectomies: standard anterior temporal lobectomy (ATL), spencer type anteromedial resection plus amigdalohippocampectomy proved to generate the best results (76% excellent and 92% favourable outcome), in agreement with published data. 17, 18 In 26 palliative surgery cases: 14 patients (53.8%) persisted with similar seizure rates, 11 patients (42.3%) showed significant decrease in frequency, and one patient (3.8%) remained seizure free after over 36 months follow up. 19, 20 
Aetiologies
In this series, patients with MTS showed the best response to surgical treatment, with 78.1% presenting excellent outcome after 1 year, and 77% showing stability over time after 60 months follow up.
Cortical dysplasias showed excellent results in 78.6% of cases in the first year, and dual pathology in 64.5%. All seven patients with brain tumors had excellent outcomes 1 year after surgery. Extratemporal resections have been generally less successful than temporal lobe resections. Recent studies report up to 57.5% of patients operated with neocortical epilepsy as seizure free after 2 years. 21 In our experience, 50% of extratemporal surgeries achieve Engel class I scores 2 years after surgery.
Antiepileptic drug requirements
The impact of surgical procedures on AE requirements contributed significantly to overall quality of life. While individual decisions on whether to reduce or withdraw AEDs were left up to the specialist, 19 patients (17.3%) were able to discontinue them entirely, 22 patients (20%) reduced the number of drugs taken, and in 12 cases (10%) dose were reduced, so that a total of 47.3% ultimately benefited with respect to medication needs after surgery. It is common for patients with difficult to control or refractory epilepsy to voice their dissatisfaction with chronic need for medication, often complaining of adverse effects, high drug costs and difficulties complying with drug schedules. A metaanalysis recently published by Schmidt showed that likelihood of interrupting AEDs was 4 times greater in surgically treated patients. 13 This fact seems of particular importance given that discontinuation or reduction of AEDs implies better psychosocial adaptation and significant cost reduction, both for patients and for health-care providers.
Morbimortality
Current surgical treatments for epilepsy are safe. 22 Eighty eight percent of all cases in this series were completed without complications, a rate similar to that described in other similar studies. 
Conclusion
Advances in diagnostic techniques and knowledge of underlying pathophysiology have increased both safety and efficacy of surgical procedures, thus increasing the number of candidates for epilepsy surgery. Most patients are potentially eligible for noninvasive methods, and up to 60-80% remain seizure-free after surgery. However, we believe conducting a successful epilepsy surgery program in a newly industrialized country is challenging, both at the technology level, as well as that of well-trained human resources. As time has elapsed, we have treated cases of increasing complexity. Early patients in the series were mostly adults subjected to resective temporal lobe surgery. More recently, refractory non-lesional focal epilepsy cases have been operated with encouraging results, although the number is too small to allow statistical analysis.
A neuro-pathology department is another important issue in a comprehensive epilepsy program. In our experience, surgical revision has enabled us to diagnose and classify cortical dysplasias that had originally gone undetected.
These results should encourage specialists in emerging economies to study this population, and to train specialized staff and acquire appropriate technology, as they indicate that results comparable to those of centres in developed countries can be achieved. Currently, we believe that early surgery represents the best opportunity available to patients with refractory epilepsy for adequate psychosocial rehabilitation and quality of life improvement.
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